Founded in 2004, ERYTECH Pharma develops innovative cancer therapies that work by starving tumours. Its first product, which is in phase III development, provides a therapeutic solution to frail patients with acute leukaemia.

ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.

The company has a production unit located in Lyons with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.


> Show all


ERYTECH today announced the launch of a sponsored American Depository Receipt (ADR) Level 1 listing in the United States in order to support the expansion of the Company’s US investor base.


ERYTECH today announced that Pierre-Olivier Goineau will be leaving the company to pursue other interests.


ERYTECH reports additional positive Phase III results from the pivotal study with ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia


ERYTECH Pharma prize winner of Deloitte Technology Fast 50 2014 Rhône-Alpes Bourgogne Auvergne


> Show all

February 9-10, 2015

Finance – ERYTECH Pharma participates on February 9-10, 2015 to BIO CEO INVESTOR Conference taking place in New York City, NY, USA

January 12-13, 2015

ERYTECH is attending JP Morgan in San Francisco, Ca, USA from January 12 to 13, 2015

December 6 - 9, 2014

SCIENTIFIC CONGRESS – ERYTECH Pharma participates in ASH annual meeting 2014 from December 6 to 9 in San Francisco, CA, USA.

November 24 - 26, 2014

FINANCE – ERYTECH Pharma attends German Equity Forum from November 24 to 26, 2014 in Frankfurt, Germany.